Modern nuclear imaging for paragangliomas: Beyond SPECT

71Citations
Citations of this article
69Readers
Mendeley users who have this article in their library.

Abstract

Paragangliomas are rare neuroendocrine tumors that may arise anywhere along the paraganglial system, with a high frequency of hereditary forms or multifocal disease. Most often, paragangliomas are benign and progress slowly, but metastases may occur in about 10% of patients. In this respect, nuclear imaging in combination with anatomic imaging may be required to fully delineate the extent of the disease. PET has been increasingly used in imaging paraganglioma, paralleled by great efforts toward the development of new tracers. Recent data indicate that the choice of PET tracers should be tailored to tumor localization and to the patient's genetic status. This article provides insight into the many PET radiotracers that are currently available and others that are still only under research and guides clinicians toward appropriate use in relation to genetic carrier status. In addition, this article provides nuclear medicine physicians with the background knowledge required for understanding relationships between imaging phenotypes and molecular genetics. Copyright © 2012 by the Society of Nuclear Medicine, Inc.

Cite

CITATION STYLE

APA

Taïeb, D., Neumann, H., Rubello, D., Al-Nahhas, A., Guillet, B., & Hindié, E. (2012, February 1). Modern nuclear imaging for paragangliomas: Beyond SPECT. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.111.098152

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free